Testing Results of Low Molecular Weight Heparin Disaccharide Enzymolysis

Method:

According to USP about Enoxaparin disaccharide enzymolysis and test method.Before adding Heparinases, you should dilute and use them according to the labeled value of the HeparinasesHeparinase I 10IU/ml, Heparinase II 4IU/ml, Heparinase III 5IU/ml).

Sample groups:

Testing liquid 1:Joint enzymolysis of Heparin sodium solution by Heparinase I,II,III.

Testing liquid 2:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III.

Testing liquid 3:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III.(Heparinase I was replaced by other lots of Heparinase I in stock).

Testing liquid 4:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III.(Heparinase II was replaced by other lots of Heparinase II in stock).

Testing liquid 5:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III.(Heparinase III was replaced by other lots of Heparinase III in stock).

Result:

As illustrated in following spectrums.

Analysis:

  • Because the experimental method is not controlling well,or the efficacy of column is not enough,the separation effect of the separation diagram is not as good as the separation diagram of EDQM,for example 1,6-androIS is inseparable from IA.
  • The enzymolysis effect of enoxaparin is sufficient,1,6-androIS at 39.3 retention time,less than 1/2 of the 1,6-androIS and IA mixed peak at 31.1 retention time.
  • Enoxaparin enzymolysis by three kinds of Heparinases,Replacing any of the three Heparinases,the peak spectrum changed little.
  • In both heparin and enoxaparin,the presence of connective regions can be seen after enzymolysis,the paek at about 19.5 retention time,but they are not high.
  • Replacing any of the three Heparinases showed little change in the peak of the junction.It shows that our Heparinases cannot make such a high peak as the connective region in the Changshan Pharmaceutical Company experiment result.Its height is also much higher than the peaks of the standard spectrum.
  • Because the instrument operating system has problems,the integration of each peak cannot be realized yet.

Testing liquid 1:Joint enzymolysis of Heparin sodium solution by Heparinase I,II,III

Testing liquid 2:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III

Testing liquid 3:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III,(Heparinase I was replaced by other lots of Heparinase I in stock)

Testing liquid 4:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III,(Heparinase II was replaced by other lots of Heparinase II in stock)

Testing liquid 5:Joint enzymolysis of Enoxaparin sodium solution by Heparinase I,II,III,(Heparinase III was replaced by other lots of Heparinase III in stock)

The Spectrum of EDQM

Heparinases for European Pharmacopoeia 9.0

As one of low-molecular-weight heparins (LWMHs), enoxaparin sodium has been manufactured as a generic anticoagulant under different brands, and regulators have been updating requirements. For example, the percentage of polysaccharide chains bearing 1,6-anhydro structure, is a big challenge for enoxaparin manufacturers, according to the test method specified in latest European Pharmacopoeia.

System suitability required by the European Pharmacopoeia Method:

– peak area ratio: maximum 1.15 for the peaks due to 1,6-anhydro ΔIS-IS and 1,6-anhydro ΔIS in the chromatogram obtained with reference solution (b);
– maximum 0.02 for the peaks due to ΔIS and reduced ΔIS in the chromatogram obtained with reference solution (c);
– resolution: minimum 1.5 between the peaks due to reduced ΔIA and 1,6-anhydro ΔIS in the chromatogram obtained with refer-ence solution (c);
– the content of 1,6-anhydro derivatives in enoxaparin sodium CRS is within 1.5 percent of the assigned content.

EP9.0 method 1097

To test the level of 1,6-anhydro species, a combination of heparinase I, heparinase II and heparinase III is used to degrade enoxaparin samples, followed by reduction via sodium tetrahydroborate. The degraded and reduced sample solutions are injected into a HPLC system for analysis.

To meet the system suitability requirements specified by European Pharmacopoeia, exhaustive depolymerization of enoxaparin samples is necessary. To achieve exhaustive depolymerization, enoxaparin manufacturers tend to use native heparinases with high purity and stability.

Through our experience in serving major enoxaparin manufacturers, Asnail has improved further native heparinases, making 1,6-anhydro derivative test for EP 1079 method more robust and confident. Now we lanuch these heparinases in separate SKUs.

To request a quote, please contact Asnail (info@asnailtech.com).

Besides, we are also developing SAX columns for determining 1,6-anhydro derivatives. Initial tests show good column performance, with the two peaks due to 1,6-anhydro ΔIS and 1,6-anhydro ΔISepi separated clearly. These SAX columns have been used by customers in China.

Significant Cost Reduction for Molecular Weight Determinations of Heparins

Asnail now offers SEC columns for molecular weight determinations that can reduce cost per injection to 1/4 or lower, compared to columns from other vendors.

BioCore SEC-HP columns
BioCore SEC-HP columns

Molecular weight (MW) and its distribution are important characteristics of heparin and low molecular weight heparins (LMWHs), a family of anticoagulants with polydisperse, heterogeneous polysaccharide chains.

Current compendial methods for heparin molecular weight determinations involve separation on size-exclusion chromatography (SEC) columns, followed by detection with refractive index detectors (RID). The resulting calibration curve relating log10(MW) to retention time can be obtained by 3rd order polynominal fitting.

Calibration curve of heparin
Calibration curve of heparin

While some SEC columns have been widely used in heparin industry before, they are subject to short life time. BioCore SEC-HP columns, a series of SEC columns tailored for heparin MW determinations, are used for MW determinations of heparin and LMWHs. The results show good performance which meets the system suitability required by the latest methods specified in pharmacopoeias. Besides, these columns show very long life time, without performance loss even after 100 injections, which can reduce cost per injection for heparin industry.

SEC chromatogram of heparin using BioCore SEC-300HP and SEC-500HP analytical columns
SEC chromatogram of heparin using BioCore SEC-300HP and SEC-500HP analytical columns
SEC chromatogram of low-molecular-weight heparin using BioCore SEC-150HP analytical column and and SEC-150 guard column
SEC chromatogram of low-molecular-weight heparin using BioCore SEC-150HP analytical column and and SEC-150 guard column

Product links

BioCore SEC-150HP Columns for Low-Molecular-Weight Heparins

BioCore SEC-300HP & SEC-500HP Columns for Unfractionated Heparins

Related documents

Asnail SEC Columns Catalog

Molecular Weight Determinations of Heparin and Low-Molecular-Weight Heparins

Asnail Products for 1,6-Anhydro Derivative Test

The percentage of 1,6-anhydro species is a unique characteristics of enoxaparin sodium, one of low-molecular-weight heparins (LWMHs) that have been widely used as anticoagulants.

1,6-Anhydro Structure in Enoxaparin Sodium

How to determine this structure?

Procedures to determine levels of 1,6-anhydro structure are listed in pharmacopeias like EP <1097> and USP <207>.

To determine the percentage of 1,6-anhydro species, enoxaparin sodium samples are first degraded via a combination of heparinases I, II and III, followed by reduction via sodium borohydride. The degraded and reduced sample solutions are injected into a HPLC system for analysis.

Typical Chromatogram of Enoxaparin Sodium

Successful analysis of this unique characteristics in enoxaparin sodium heavily depends on the choice of right HPLC columns and heparinases.

Why choose Asnail?

For analysis of 1,6-anhydro species in enoxaparin sodium, Asnail offers heparinases, heparin-derived unsaturated disaccharides, and SAX columns.

Heparinases are the most important and expensive reagents used in QA of enoxaparin sodium. Asnail’s native heparinases feature great stability and purity. By now, Asnail’s heparinases have served many customers whose procedures are in compliance with EN and USP.

Heparinase I, II, and III for Degrading Enoxaparin Sodium

To identify peaks in chromatograms, Asnail provides heparin unsaturated disaccharides as reference materials which are prepared by degrading heparin and/or heparan sulfate via heparinases.

Heparin Disaccharides for Peak Identification

For HPLC columns, Asnail has tested and selected the Ultisil XB-SAX analytical column, which has proved to provide better performance than previously available columns. This column is co-developed with Welchmat, a long-time parter of Asnail.

XB-SAX Column for Analysis of 1,6-Anhydro Structure

Product links

Heparinases from Flavobacterium heparinum

Heparin-derived unsaturated disaccharides

Ultisil XB-SAX column for 1,6-anhydro test

Chromogenic Substrates for Factor VIII Assay

Asnail now offers chromogenic substrates (S-2222 and S-2765) for factor VIII assay. The chromogenic assay is recommended for clinical diagnosis of haemophilia, monitoring factor replacement therapies and potency assignment of recombinant factor VIII.

Coagulation factor VIII (FVIII) performs a critical role in the intrinsic blood coagulation pathway. The typical quantitative chromogenic assay for coagulation factor VIII is specified in European Pharmacopoeia, as a two-stage procedure.

Chromogenic Assay of Factor VIII

In this assay, coagulation factor VIII first catalyzes the transformation of factor X into its activated form, factor Xa, which in turn catalyzes the release of pNA from the substrate (S-2222 or S-2765). The potency of coagulation factor VIII is deduced by measuring the chromophore, pNA.

Asnail now offers two chromogenic substrates for this assay.

Chromogenic Substrates for Coagulation Testing

Asnail now offers chromogenic substrates in gram grade for coagulation testing.

These large-quantity chromogenic substrates can be used in chromogenic assay kits.

For more information, please contact us via info@asnailtech.com.

Chromogenic Assays for Heparin

Asnail now offers a wide range of reagents used in chromogenic assays for heparin.

Chromogenic Substrates

Asnail’s chromogenic substrates including:

S-2238, Chromogenic Substrate for Thrombin

S-2222, Chromogenic Substrate for Factor Xa

S-2765, Chromogenic Substrate for Factor Xa

Coagulation Factors

Asnail’s coagulation factors including:

Activated Factor X (FXa)

Alpha-Thrombin (FIIa)

Antithrombin

Asnail provides human antithrombin for both anti-FIIa and anti-FXa assays.

Human Antithrombin

With our expertise in heparin analysis, we also offer technical support with regard to chromogenic assays for heparin and LMWHs.

For more information, please contact us.

Asnail offers Abciximab

Dear customers,

Asnail now officially offers Abciximab for research and development use.

Abciximab (ReoPro) is a glycoprotein IIb/IIIa receptor antagonist involved in coagulation cascade. Along with our heparinases and chromogenic substrates, we offer Abciximab for coagulation testing.

You can click the following link to know more about Abciximab.

Abciximab

For more information, please contact us via email (jay@asnailtech.com).

Asnail Global Website Redesigned

Dear customers,

Asnail’s global website (www.asnailtech.com) is being redesigned and will launch later April 2019.

Our new website aims to providing customers with high-quality products, used in application such as heparin analysis and coagulation testing.

The new website also will feature better user experience.

Stay tuned.